prod:prod_dcx-login
Xpert® Breast Cancer STRAT4
Standardized breast cancer ESR1/PGR/ERBB2/MKi67 mRNA biomarker assessment in less than two hours
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXBCSTRAT4-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
1 Tests
GXFFPE-LYSIS-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Breast cancer biomarker ER/PGR/HER2/Ki-67 results need to be dependable and objective
- Clinicians need more reliable ER/PGR/HER2/Ki-67 assessment in FFPE tumor tissues.
- 5% of HER2 IHC results are equivocal based upon guide line recommended classifications.1
- Resolving HER2 IHC2+ equivocal results with FISH is challenging.1-4
- Technical and observer variability can lead to approximately 20% inaccurate ER and PGR results.5
- Ki-67 IHC scores deviate due to a lack of standardization.6
(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6)Polley MYC et a.l An International Ki67 Reproducibility Study. J Natl Cancer Ins. 2013 Dec 18;105(24):1897-906.
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6)Polley MYC et a.l An International Ki67 Reproducibility Study. J Natl Cancer Ins. 2013 Dec 18;105(24):1897-906.
The Solution
Xpert® Breast Cancer STRAT4 paves the way for a standardized, precise and reliable ER/PGR/HER2/Ki-67 mRNA assessment in less than 2 hours
- Xpert Breast Cancer STRAT4 delivers semi-quantitative determination of ER/PGR/HER2/Ki-67 mRNA levels in FFPE invasive breast cancer sections
- CYFIP1* reference gene is used for sample normalization
- Three controls included in each test
- Software report allows for objective and easy result interpretation
- External FFPE controls# available for identifying errors, shifts, trends and operator variabilities
CYFIP1: Cytoplasmic FMR1 interacting protein 1
# For Research Use Only. Not for use in diagnostic procedure. Not reviewed by any regulatory body.
# For Research Use Only. Not for use in diagnostic procedure. Not reviewed by any regulatory body.
The Impact
Xpert Breast Cancer STRAT4 standardizes reproducible ER/PGR/HER2/Ki-67 assessment
Xpert Breast Cancer STRAT4 results are highly concordant with ER/PGR/Ki-67 IHC and IHC/FISH (HER2)7
Positivity detection cut-offs of Xpert Breast Cancer STRAT4 for ER/PGR/HER2 correlate with those in ASCO-CAP, St. Gallen Consensus and ESMO Guidelines.1,5,8,9
- Clear and accurate results empower oncologists.
- Enables flexibility, simplicity and random access for a streamlined workflow 24/7.
- Easy and fast test implementation.
- Internal controls meet quality management requirements.
- Robust test and workflow that doesn't require a PCR laboratory.
Xpert Breast Cancer STRAT4 results are highly concordant with ER/PGR/Ki-67 IHC and IHC/FISH (HER2)7
| Xpert Breast Cancer STRAT4 vs. IHC biomarker assessment | PPA | NPA | OPA |
|---|---|---|---|
| ESR1/ER | 97.2% | 95.0% | 97.5% |
| PR/PGR | 89% | 92.9% | 89.8% |
| ERBB2/HER2 (Xpert vs IHC) | 100% | 92.4% | 93.3% |
| ERBB2/HER2 (Xpert vs FISH) | 100% | 92.0% | 93.3% |
| ERBB2/HER2 (Xpert vs. IHC+FISH) | 100% | 91.2% | 92.4% |
| MKi-67/Ki-67 | 88.7% | 100% | 90.5% |
(7)Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale. USA. 2017
(8)Gnant M et al. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care. 2015 Apr;10(2):124-130.
(9)Senkus et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.# For Research Use Only. Not for use in diagnostic procedures.* CE-IVD. In Vitro Medical Device. Not available in the U.S. Not available in all countries.^ Limited to one per customer.
(8)Gnant M et al. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care. 2015 Apr;10(2):124-130.
(9)Senkus et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26 Suppl 5:v8-30.# For Research Use Only. Not for use in diagnostic procedures.* CE-IVD. In Vitro Medical Device. Not available in the U.S. Not available in all countries.^ Limited to one per customer.
Related Products
Expert Bladder Cancer Monitor
Qualitative monitoring for recurrence in patients previously diagnosed with bladder cancer in around 90 minutes
Xpert Bladder Cancer Detection
Detection of the presence of bladder cancer in patients with hematuria in around 90 minutes
Xpert BCR-ABL Ultra
Sensitive and quantitative monitoring of BCR-ABL mRNA in patients with chronic myelogenous leukemia (CML)
Xpert FII & FV
30-Minute Test for Genetic Risk of Thrombosis